CY1792A - Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine - Google Patents

Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine

Info

Publication number
CY1792A
CY1792A CY179295A CY179295A CY1792A CY 1792 A CY1792 A CY 1792A CY 179295 A CY179295 A CY 179295A CY 179295 A CY179295 A CY 179295A CY 1792 A CY1792 A CY 1792A
Authority
CY
Cyprus
Prior art keywords
dideoxyguanosine
dideoxyadenosine
dideoxyinosine
htlv
iii
Prior art date
Application number
CY179295A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25084165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of CY1792A publication Critical patent/CY1792A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY179295A 1985-08-26 1995-10-20 Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine CY1792A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76901685A 1985-08-26 1985-08-26

Publications (1)

Publication Number Publication Date
CY1792A true CY1792A (en) 1995-10-20

Family

ID=25084165

Family Applications (1)

Application Number Title Priority Date Filing Date
CY179295A CY1792A (en) 1985-08-26 1995-10-20 Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine

Country Status (16)

Country Link
US (1) US4861759A (de)
EP (1) EP0216510B1 (de)
JP (1) JPS62501712A (de)
AT (1) ATE96325T1 (de)
AU (1) AU570853B2 (de)
CA (1) CA1269044A (de)
CY (1) CY1792A (de)
DE (1) DE3689220T2 (de)
HK (1) HK47694A (de)
IE (1) IE64518B1 (de)
IL (1) IL79700A (de)
LU (1) LU88475I2 (de)
MX (1) MX9203377A (de)
NL (1) NL940005I2 (de)
NZ (1) NZ217185A (de)
WO (1) WO1987001284A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512330D0 (en) * 1985-05-15 1985-06-19 Wellcome Found Antiviral compounds
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
IL86009A (en) * 1987-04-10 1991-09-16 Us Health Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
US5028595A (en) * 1987-09-18 1991-07-02 Hoffmann-La Roche Inc. Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5571839A (en) * 1989-04-28 1996-11-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) D-aspartic acid β-hydroxamate for the treatment of viral infections and tumors
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
US6207650B1 (en) * 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
AU5832990A (en) * 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5221611A (en) * 1991-06-19 1993-06-22 Sigma Chemical Company Ddi immunoassays, derivatives, conjugates and antibodies
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
WO1995017875A2 (en) * 1993-12-20 1995-07-06 Compagnie De Developpement Aguettant MIXTURES OF DIDEOXYNUCLEOSIDES AND D-ASPARTIC ACID β-HYDROXAMATE FOR INHIBITING RETROVIRAL SPREAD
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
EP0831852B1 (de) * 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000136136A (ja) * 1998-10-30 2000-05-16 Fujirebio Inc 抗ウイルス剤
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CA2270600A1 (en) 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
RU2158592C1 (ru) * 1999-12-29 2000-11-10 Каплина Элли Николаевна Противовирусное иммунотропное средство
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
RU2188659C1 (ru) * 2001-04-20 2002-09-10 ООО Научно-производственное фармацевтическое предприятие "Полидан" Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
ME03423B (de) 2004-07-27 2020-01-20 Gilead Sciences Inc Phosphonat Analoga von HIV Inhibitor Verbindungen
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治疗hiv的toll样受体(tlr)调节剂
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4112221A (en) * 1974-07-17 1978-09-05 Asahi Kasei Kogyo Kabushiki Kaisha Process for preparing 8,2'-O-anhydropurine nucleosides
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS59104399A (ja) * 1982-12-03 1984-06-16 Takeda Chem Ind Ltd ヌクレオチドおよびヌクレオシドの相互分離方法
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.

Also Published As

Publication number Publication date
AU570853B2 (en) 1988-03-24
DE3689220D1 (de) 1993-12-02
WO1987001284A1 (en) 1987-03-12
IE64518B1 (en) 1995-08-09
CA1269044A (en) 1990-05-15
JPH0215523B2 (de) 1990-04-12
EP0216510B1 (de) 1993-10-27
MX9203377A (es) 1992-09-01
JPS62501712A (ja) 1987-07-09
HK47694A (en) 1994-05-20
EP0216510A2 (de) 1987-04-01
IE940570L (en) 1987-02-26
NL940005I1 (nl) 1994-05-16
IL79700A (en) 1991-09-16
ATE96325T1 (de) 1993-11-15
AU6196886A (en) 1987-03-24
NZ217185A (en) 1990-03-27
IE862265L (en) 1987-02-26
IL79700A0 (en) 1986-11-30
US4861759A (en) 1989-08-29
NL940005I2 (nl) 1999-08-02
LU88475I2 (fr) 1994-09-09
DE3689220T2 (de) 1994-02-24
EP0216510A3 (en) 1989-08-02

Similar Documents

Publication Publication Date Title
CY1792A (en) Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine or 2'3'-dideoxyadenosine
AU1625988A (en) Dynamic energy absorber
EP0216511A3 (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2'3'-dideoxycytidine
DK165906C (da) Smoeremetode under anvendelse af ioniserende plasma, samt genstand hvortil smoeremetoden anvendes
NO169834C (no) Fremgangsmaate for fremstilling av mono- og diolefiner fraparafiner ved anvendelse av en syklisk, adiabatisk, katalystisk dehydrogeneringsreaktor
IL79964A0 (en) Process for the preparation of optically active alpha-phenoxy-propionic acid and its derivatives
GB2188292B (en) Vehicles modified to accomodate wheel chairs
SG32294G (en) Inhibition of in vitro infecivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine
EP0331455A3 (de) Abschirmvorrichtung und Abschirmungsverfahren
EP0200436A3 (de) 12b-Substituierte 1-Hydroxymethyl-octahydroindolo[2,3-a]-chinolizinderivate
DE3665168D1 (en) Oculoselective beta blockers
MY101451A (en) Crystalline form of 7-(dimethylaminothylene) amino-9a-methoxymitosane
USD277975S (en) Amusement ride
IT1210865B (it) Procedimento ed apparecchiatura per correggere le asimmetricita' di centratura di una ruota a raggi in senso parallelo all'asse della ruota.
USD263297S (en) In-line lamp dimmer
EP0213626A3 (en) Process for the fabrication of modified epoxy resins
PT83116A (en) Process for the preparation of 5-chloro-s-triazolo <4,3-a> pyridine-7-carboxylic acids
AU2342388A (en) A device for the attachment of carrycots to children's pushchairs
EP0173480A3 (de) Die antivirale Verwendung von Phyllanthostatinen
FI921177L (fi) Menetelmä 9-(1,3-dihydroksi-2-propoksimetyyli)-guaniinijohdannaisten valmistamiseksi
AU6109386A (en) Reuse of heat energy
FR2564452B1 (fr) Procede de preparation d'ammoniac et ammoniac obtenu par ledit procede
SE8501703D0 (sv) Process for the preparation of polyethylene polyamines
IT1221164B (it) Pinna natatoria per l' apprendimento del muoto
IT8220297A0 (it) Procedimento per la preparazione di una sospensione di zeolite dotatadi eccellente stabilita' statica edi eccellente stabilita' dinamica.